Prism Medico and Pharmacy Limited Q2 Results Due November 5

Prism Medico and Pharmacy Limited is scheduled to consider its unaudited standalone Q2 FY27 results for the quarter ended September 30, 2026, on November 5, following a Q1 FY27 net loss of ₹0.0583 crore and zero revenue from operations. The release matters because the company’s recent disclosures show limited operating income and continuing losses.

When will Prism Medico announce its Q2 FY27 results?

Prism Medico is scheduled to report its Q2 FY27 outcome on November 5, 2026. The stated agenda is a board meeting to approve unaudited standalone financial results for the quarter ended September 30, 2026.

The company’s earnings calendar also identifies November 5 as the next results date. The available information does not provide Q2 revenue, profit, expense, balance-sheet or cash-flow figures before the board’s consideration. Accordingly, investors will need to rely on the formal financial results and related exchange filing for the reported numbers.

What did Prism Medico report in Q1 FY27?

Prism Medico reported a net loss of ₹0.0583 crore for Q1 FY27, while revenue from operations was zero. The Q1 result, reported on August 12, 2026, showed total expenses of ₹0.1489 crore, with other expenses and employee-benefit expenses identified as the primary expense categories.

The data supplied for the upcoming earnings page also shows revenue, gross profit and net profit as zero, alongside large quarter-on-quarter and year-on-year percentage changes. However, no underlying figures or detailed calculation for those summary fields are supplied. The confirmed Q1 disclosure is therefore the clearer reference point ahead of the September-quarter announcement.

How do the latest figures compare with Prism Medico’s earlier results?

Prism Medico’s disclosed half-yearly figures show a wide variation in operating scale across earlier periods. For the half year ended March 2026, net sales turnover was ₹0.35 crore and reported PAT was a loss of ₹0.25 crore. In the half year ended September 2025, net sales turnover was ₹2.09 crore and reported PAT was a profit of ₹0.57 crore.

Older quarterly information for the quarter ended December 2019 recorded sales of ₹9.75 crore and a net loss of ₹0.04 crore. That sales figure was stated to be 43.1% lower than ₹17.13 crore in the corresponding quarter a year earlier. These historical figures provide context, but they are from periods substantially earlier than the current financial year and should not be treated as a guide to the forthcoming Q2 result.

Why do Prism Medico’s Q2 FY27 results matter to investors?

Prism Medico’s Q2 FY27 results matter because the Q1 filing reported no revenue from operations while expenses continued, resulting in a loss. The September-quarter statement will show whether operating revenue resumed, whether costs changed, and whether the company remained loss-making during the first half of FY27.

The results will also be relevant for assessing the consistency of the company’s disclosed business activity. The available material describes Prism Medico as selling pharmaceutical products in India, while a separate company-profile entry describes wholesaling and retailing of straw, fodder, and other animal or poultry feed. The supplied information does not reconcile these descriptions. Investors may therefore look to the financial statements, directors’ report and business disclosures for clarity on operations.

What disclosures should investors monitor after the board meeting?

Investors should monitor the revenue-from-operations line, total expenses, net profit or loss, and any explanatory notes released with the unaudited standalone results. A comparison with the Q1 FY27 loss of ₹0.0583 crore and ₹0.1489 crore of expenses will help establish whether the September quarter showed a material change in operating performance.

The company held its 24th annual general meeting on September 19, 2026, and its annual financial statements for the year ended March 31, 2026 were placed before shareholders for adoption. The Q2 filing is the next scheduled financial disclosure identified in the supplied information. No analyst consensus estimate, revenue target or management outlook for Q2 FY27 is provided.

Conclusion

Prism Medico enters its Q2 FY27 results date after a first quarter in which it reported zero operating revenue and a ₹0.0583 crore net loss. The disclosed history shows uneven sales and profitability across periods, making the September-quarter figures important for establishing the company’s current operating position.

The next item to watch is the board’s approval and publication of unaudited standalone Q2 FY27 results for the quarter ended September 30, 2026. Investors can then assess reported revenue, expenses, profitability and any clarification provided on the company’s underlying business operations.